Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors

LESSONS LEARNED. Ramucirumab was well tolerated in Chinese patients with advanced solid tumors, and adverse events were manageable in this study. Pharmacokinetics characteristics in Chinese patients were similar to those in other populations. Immunogenicity was not detected. No efficacy conclusion c...

Full description

Saved in:
Bibliographic Details
Published in:Oncologist
Main Authors: Cao, Junning, Ji, Dongmei, Chen, Zhiyu, Shen, Weina, Wang, Jin, Li, Baoyue, Chi, Haidong, Long, Amanda, Gao, Ling, Li, Jin
Format: Artigo
Language:Inglês
Published: AlphaMed Press 2017
Subjects:
Clinical Trial Results
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5469595/
https://ncbi.nlm.nih.gov/pubmed/28465370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0137
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items